In low-dose oral solid dosage form development, the compound is typically introduced as a pre-sieved active fraction after pin-milling or jet-milling to a particle size distribution of D90 ≤ 30 µm, because the pinanediol boronate ester motif is susceptible to moisture-induced hydrolysis during aqueous processing. Direct compression is used only when the active fraction can be blended as a dry powder; release testing is anchored to USP <711> Apparatus 2, USP <905> for content uniformity, USP <701> for disintegration, and ICH Q3D for elemental impurities. Representative pre-formulation addition ratios at pilot scale are 0.5–5.0% w/w for the active fraction, 60–85% w/w microcrystalline cellulose 102, 10–25% w/w dibasic calcium phosphate anhydrous, 2–5% w/w croscarmellose sodium, 0.5–1.0% w/w colloidal silicon dioxide, and 0.25–1.0% w/w magnesium stearate. The process is run on a 16-station rotary tablet press with B-tooling at a main compression force of 8–18 kN and precompression of 3–6 kN; powder flow is controlled to an angle of repose ≤ 35° and Hausner ratio ≤ 1.25. Scale-up lots on a 30-litre bin blender typically require a 3–5 min final lubrication step and a 15 min total blend time after geometric dilution. Tablets are compacted to 80–120 N hardness with friability ≤ 1.0% and disintegration ≤ 15 min. Manufacturing under relative humidity above 60% requires pre-drying of excipients and shortened compression campaigns because the pinanediol ester is hydrolytically labile. The terminal product type is an immediate-release tablet, not an enteric-controlled or extended-release system unless a functional coating is added after compression.

What Changes When the Same Active Fraction Is Filled into Hard Capsules?

Encapsulation avoids the compaction stresses that can destabilize the pinanediol ester and instead shifts the critical controls to powder flow, fill weight consistency, and shell–fill compatibility. The active fraction is typically reduced to D90 ≤ 50 µm and blended at 1.0–8.0% w/w with 60–85% w/w lactose monohydrate or mannitol, 5–15% w/w pregelatinized starch, 2–6% w/w sodium starch glycolate, 0.5–1.0% w/w colloidal silicon dioxide, and 0.5–1.5% w/w sodium stearyl fumarate as a lubricant. Industry compliance for release testing is built around USP <905>, USP <701> for disintegration, USP <711> Apparatus 1 or 2 with a surfactant-containing medium, USP <467> for residual solvents, and ICH Q3C. The downstream process uses a 100-litre V-blender at 25 rpm for 10 min after a 12 rpm preblend step, then fills size 0 or 1 hard gelatin or hydroxypropyl methylcellulose shells on a dosator machine at approximately 30,000 capsules/h. Fill weight is maintained at 200–350 mg with relative standard deviation ≤ 2.0%; batch records flag dosator plug compression above 30 N because it can increase fill weight variability and split the shell shoulder. The terminal product type is a hard capsule for oral administration, sharing the same active fraction as the tablet but without a tablet-hardness specification.

Granular intermediates for unit-dose sachet filling are manufactured when the dosage form must be dispersed in water or taken directly as oral granules; the process converts the active fraction into a free-flowing, dust-reduced bed that can be filled volumetrically. In this scenario, the active fraction is added at 0.5–4.0% w/w, mannitol at 70–85% w/w, hypromellose 2910 as binder at 3–5% w/w, crospovidone at 2–5% w/w, citric acid monohydrate at 0.5–1.5% w/w for pH adjustment, and colloidal silicon dioxide at 0.5–1.0% w/w. Because the pinanediol ester is moisture-sensitive, aqueous high-shear granulation is justified only when stability data confirm that granule moisture below 2.0% w/w can be achieved without ester hydrolysis; otherwise dry granulation should replace this route. The downstream process uses a 25-litre high-shear granulator with an impeller speed of 200–400 rpm and chopper speed of 1500–3000 rpm, followed by fluid-bed drying at an inlet air temperature of 50–70 °C and product temperature of 35–45 °C to a loss-on-drying endpoint of 2–4% w/w. Dried granules are sieved through a 0.8 mm screen, final-blended for 10 min, and filled into single-dose sachets on an auger or volumetric filler at fill weights of 500–2000 mg. Release testing is anchored to Ph. Eur. 2.9.1 and USP <701> for disintegration, Ph. Eur. 2.9.3 and USP <711> for dissolution, and ICH Q3D for elemental impurities. The terminal product type is a unit-dose granule for oral administration, which may be swallowed directly or dispersed in water; it is not an injectable granulate.

When Lyophilization Is Required for an Injectable Boronate Ester API

For a boronate-pinanediol active fraction intended for intravenous or subcutaneous administration, lyophilization is used when aqueous solution-state stability data show unacceptable hydrolysis of the pinanediol ester at room temperature or under terminal sterilization heat. The pre-lyophilization solution is commonly prepared with the active fraction at 0.05–0.50% w/v, mannitol as a bulking agent at 30–50 mg/mL, a trometamol or citrate buffer to maintain pH 5.5–7.4, and polysorbate 20 at 0.01–0.2% v/v when surface adsorption to glass is observed. Compliance for the sterile product is anchored to USP <1>, USP <71> sterility, USP <85> bacterial endotoxins, USP <788> particulate matter, ICH Q3B for degradation products, and EU GMP Annex 1 for aseptic processing. The manufacturing sequence begins with dissolution in WFI at 20–25 °C, pH adjustment with dilute hydrochloric acid or sodium hydroxide, sterile filtration through a 0.22 µm PVDF membrane, and filling into 10R borosilicate glass vials to 2.0–5.0 mL fill volume. Lyophilization cycles on a 12 m² shelf freeze-dryer typically use freezing at -40 to -50 °C for 2–4 h, primary drying at -20 to -10 °C under 100–200 mTorr chamber pressure, and secondary drying at +25 to +35 °C under 50–100 mTorr to a cake moisture below 2.0% w/w. Published product-specific lyophilization cycle data for this exact compound are limited; the cycle described is a platform for a low-solubility boronate ester. The terminal product type is a lyophilized powder for injection or infusion that is reconstituted with 0.9% sodium chloride injection or sterile water for injection; it is not a ready-to-use solution.

Ready-to-Dilute Injectable Solution and Terminal Sterilization Constraints

A ready-to-dilute solution route is selected only when accelerated stability studies demonstrate that the pinanediol ester remains within specification in a non-aqueous or mixed aqueous-organic matrix; aqueous ready-to-use formulations are generally avoided because the ester undergoes hydrolysis above 60 °C and over extended storage at neutral pH. In this formulation, the active fraction is dissolved at 0.1–1.0 mg/mL in a vehicle containing 10–40% v/v PEG 300 or propylene glycol, 0.9% sodium chloride or 5% dextrose for tonicity, 0.01–0.2% v/v polysorbate 20, and citrate or phosphate buffer to pH 5.5–7.4. The solution is compounded under nitrogen at 20–25 °C, filtered through a 0.22 µm PVDF membrane, and aseptically filled in single-dose vials under Grade A conditions; terminal moist-heat sterilization is excluded from the process because of hydrolysis risk. Compliance is anchored to USP <1>, USP <788> subvisible particulate matter, USP <790> visible particulates, USP <1207> container closure integrity, ICH Q3B, ICH Q3C, and 21 CFR 211.113 for microbiological control. Scale-up batches on a 200-vial-per-minute filling line require 0.2–0.5% nitrogen purge and light-protected glass to limit oxidative and photolytic degradation; subvisible particulate counts remain below 6000 per container for particles ≥ 10 µm and 600 per container for particles ≥ 25 µm as per USP <788>. Published formulation data for this exact compound are limited; the ratios are platform starting points that require product-specific stability confirmation. The terminal product type is a sterile, ready-to-dilute solution for infusion, not a final intravenous bolus unless diluted into an approved carrier.

For low-dose tablet formulations in which the active fraction segregates during direct compression or shows poor flow, dry granulation by roller compaction is inserted between blending and compression to densify the powder into ribbons before milling. The active fraction is blended at 1.0–6.0% w/w with 60–80% w/w microcrystalline cellulose 102, 10–25% w/w anhydrous lactose, 2–5% w/w crospovidone, 0.5–1.0% w/w colloidal silicon dioxide, and 0.25–1.0% w/w magnesium stearate added before and after compaction in a split lubrication step. Production-scale roller compaction uses roll force 8–15 kN/cm, roll gap 2–4 mm, and an 0.8–1.25 mm mill screen; ribbon density is controlled to 1.1–1.4 g/cm³ to avoid excessive hardness and delayed disintegration. Release testing follows USP <905>, USP <711> Apparatus 2, USP <701>, and ICH Q3D. The final granule is compressed on a 16-station rotary press at 10–20 kN, with tablet hardness 90–130 N, friability ≤ 1.0%, and disintegration ≤ 15 min. The terminal product type is an immediate-release tablet manufactured by dry granulation rather than direct compression, used when batch-to-batch flow variability is observed on direct-compression lines.